ID   GBA3_HUMAN              Reviewed;         469 AA.
AC   Q9H227; Q32LY7; Q3MIH4; Q53GG8; Q6NSF4; Q8NHT8; Q9H3T4; Q9H4C6;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   10-MAY-2017, entry version 139.
DE   RecName: Full=Cytosolic beta-glucosidase;
DE            EC=3.2.1.21;
DE   AltName: Full=Cytosolic beta-glucosidase-like protein 1;
GN   Name=GBA3; Synonyms=CBG, CBGL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal liver;
RX   PubMed=11043382; DOI=10.1007/s001090000131;
RA   Yahata K., Mori K., Arai H., Koide S., Ogawa Y., Mukoyama M.,
RA   Sugawara A., Ozaki S., Tanaka I., Nabeshima Y., Nakao K.;
RT   "Molecular cloning and expression of a novel klotho-related protein.";
RL   J. Mol. Med. 78:389-394(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Liver;
RX   PubMed=11389701; DOI=10.1042/0264-6021:3560907;
RA   de Graaf M., van Veen I.C., van der Meulen-Muileman I.H.,
RA   Gerritsen W.R., Pinedo H.M., Haisma H.J.;
RT   "Cloning and characterization of human liver cytosolic beta-
RT   glycosidase.";
RL   Biochem. J. 356:907-910(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BLOCKAGE OF
RP   N-TERMINUS, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Liver;
RX   PubMed=11784319; DOI=10.1046/j.0014-2956.2001.02641.x;
RA   Berrin J.-G., McLauchlan W.R., Needs P., Williamson G., Puigserver A.,
RA   Kroon P.A., Juge N.;
RT   "Functional expression of human liver cytosolic beta-glucosidase in
RT   Pichia pastoris. Insights into its role in the metabolism of dietary
RT   glucosides.";
RL   Eur. J. Biochem. 269:249-258(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Hays W.S., VanderJagt D.J., Glew R.H., Johnston D.E.;
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Small intestine;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   MUTAGENESIS OF VAL-168; PHE-225 AND TYR-308.
RX   PubMed=12667141; DOI=10.1042/BJ20021876;
RA   Berrin J.-G., Czjzek M., Kroon P.A., McLauchlan W.R., Puigserver A.,
RA   Williamson G., Juge N.;
RT   "Substrate (aglycone) specificity of human cytosolic beta-
RT   glucosidase.";
RL   Biochem. J. 373:41-48(2003).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12594539; DOI=10.1007/s00394-003-0397-3;
RA   Nemeth K., Plumb G.W., Berrin J.-G., Juge N., Jacob R., Naim H.Y.,
RA   Williamson G., Swallow D.M., Kroon P.A.;
RT   "Deglycosylation by small intestinal epithelial cell beta-glucosidases
RT   is a critical step in the absorption and metabolism of dietary
RT   flavonoid glycosides in humans.";
RL   Eur. J. Nutr. 42:29-42(2003).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH GLUCOSE AND
RP   GALACTOSE, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLU-165
RP   AND GLU-373.
RX   PubMed=17595169; DOI=10.1074/jbc.M700832200;
RA   Hayashi Y., Okino N., Kakuta Y., Shikanai T., Tani M., Narimatsu H.,
RA   Ito M.;
RT   "Klotho-related protein is a novel cytosolic neutral beta-
RT   glycosylceramidase.";
RL   J. Biol. Chem. 282:30889-30900(2007).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RX   PubMed=17555766; DOI=10.1016/j.jmb.2007.05.034;
RA   Tribolo S., Berrin J.G., Kroon P.A., Czjzek M., Juge N.;
RT   "The crystal structure of human cytosolic beta-glucosidase unravels
RT   the substrate aglycone specificity of a family 1 glycoside
RT   hydrolase.";
RL   J. Mol. Biol. 370:964-975(2007).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH GLUCOSE, AND
RP   MUTAGENESIS OF GLU-165.
RX   PubMed=18662675; DOI=10.1016/j.bbrc.2008.07.089;
RA   Noguchi J., Hayashi Y., Baba Y., Okino N., Kimura M., Ito M.,
RA   Kakuta Y.;
RT   "Crystal structure of the covalent intermediate of human cytosolic
RT   beta-glucosidase.";
RL   Biochem. Biophys. Res. Commun. 374:549-552(2008).
RN   [12]
RP   VARIANT ASN-106.
RX   PubMed=15322500; DOI=10.1016/j.lab.2004.03.013;
RA   Beutler E., Beutler L., West C.;
RT   "Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher
RT   disease.";
RL   J. Lab. Clin. Med. 144:65-68(2004).
CC   -!- FUNCTION: Glycosidase probably involved in the intestinal
CC       absorption and metabolism of dietary flavonoid glycosides. Able to
CC       hydrolyze a broad variety of glycosides including phytoestrogens,
CC       flavonols, flavones, flavanones and cyanogens. Possesses beta-
CC       glycosylceramidase activity and may be involved in a nonlysosomal
CC       catabolic pathway of glycosylceramide.
CC       {ECO:0000269|PubMed:11784319, ECO:0000269|PubMed:12594539,
CC       ECO:0000269|PubMed:17595169}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal, non-reducing beta-D-
CC       glucosyl residues with release of beta-D-glucose.
CC   -!- ENZYME REGULATION: Inhibited by 2,4-dinitrophenyl-2-fluoro-2-
CC       deoxy-beta-D-glucopyranoside and sodium taurocholate.
CC       {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=40 uM for 4-methylumbelliferyl-beta-D-glucopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=50 uM for 4-methylumbelliferyl-beta-D-galactopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=370 uM for 4-nitrophenyl-beta-D-fucopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=570 uM for 4-nitrophenyl-alpha-D-arabinopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=1.76 mM for 4-nitrophenyl-beta-D-glucopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=3.14 mM for 4-nitrophenyl-beta-D-galactopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=1.58 mM for 4-nitrophenyl-beta-D-xylopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=52.6 mM for 4-nitrophenyl-beta-L-arabinopyranoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=35 uM for genistein-7-glucoside {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC         KM=118 uM for daidzein-7-glucoside {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC         KM=31.8 uM for quercetin-4'-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=42.2 uM for quercetin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=21.5 uM for apigenin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=10 uM for luteolin-4'-glucoside {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC         KM=50 uM for luteolin-7-glucoside {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC         KM=432 uM for naringenin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         KM=253 uM for eriodictyol-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=10 umol/min/mg enzyme toward 4-nitrophenyl-beta-D-
CC         glucopyranoside {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC         Vmax=1.73 umol/min/mg enzyme toward genistein-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=2.75 umol/min/mg enzyme toward daidzein-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=1.19 umol/min/mg enzyme toward quercetin-4'-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=0.77 umol/min/mg enzyme toward quercetin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=1.30 umol/min/mg enzyme toward apigenin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=1.30 umol/min/mg enzyme toward luteolin-4'-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=2.85 umol/min/mg enzyme toward luteolin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=0.93 umol/min/mg enzyme toward naringenin-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC         Vmax=0.90 umol/min/mg enzyme toward eriodictyol-7-glucoside
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC       pH dependence:
CC         Optimum pH is 6.5. Active from pH 5 to 7.5. Activity decreases
CC         sharply with increasing acidity and is less than 4% at pH 4.
CC         {ECO:0000269|PubMed:11389701, ECO:0000269|PubMed:11784319};
CC       Temperature dependence:
CC         Optimum temperature is 50 degrees Celsius. Stable more than 24
CC         hours at 37 degrees Celsius. Loses activity at 58 degrees
CC         Celsius. {ECO:0000269|PubMed:11389701,
CC         ECO:0000269|PubMed:11784319};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:12594539, ECO:0000269|PubMed:17595169}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9H227-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H227-2; Sequence=VSP_015835;
CC   -!- TISSUE SPECIFICITY: Present in small intestine (at protein level).
CC       Expressed in liver, small intestine, colon, spleen and kidney.
CC       Down-regulated in renal cell carcinomas and hepatocellular
CC       carcinomas. {ECO:0000269|PubMed:11043382,
CC       ECO:0000269|PubMed:12594539}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 1 family. Klotho
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB017913; BAB18741.1; -; mRNA.
DR   EMBL; AJ278964; CAC08178.1; -; mRNA.
DR   EMBL; AF317840; AAG39217.1; -; mRNA.
DR   EMBL; AF323990; AAL37305.1; -; mRNA.
DR   EMBL; AK222963; BAD96683.1; -; mRNA.
DR   EMBL; BC029362; AAH29362.1; -; mRNA.
DR   EMBL; BC070188; AAH70188.1; -; mRNA.
DR   EMBL; BC101829; AAI01830.1; -; mRNA.
DR   EMBL; BC109377; AAI09378.1; -; mRNA.
DR   RefSeq; NP_001121904.1; NM_001128432.2. [Q9H227-2]
DR   RefSeq; NP_001264154.1; NM_001277225.1.
DR   RefSeq; NP_066024.1; NM_020973.4. [Q9H227-1]
DR   UniGene; Hs.653107; -.
DR   PDB; 2E9L; X-ray; 1.60 A; A=1-469.
DR   PDB; 2E9M; X-ray; 1.80 A; A=1-469.
DR   PDB; 2JFE; X-ray; 2.70 A; X=1-469.
DR   PDB; 2ZOX; X-ray; 1.90 A; A=1-469.
DR   PDB; 3VKK; X-ray; 2.00 A; A=1-469.
DR   PDBsum; 2E9L; -.
DR   PDBsum; 2E9M; -.
DR   PDBsum; 2JFE; -.
DR   PDBsum; 2ZOX; -.
DR   PDBsum; 3VKK; -.
DR   ProteinModelPortal; Q9H227; -.
DR   SMR; Q9H227; -.
DR   BioGrid; 121753; 2.
DR   IntAct; Q9H227; 2.
DR   STRING; 9606.ENSP00000471397; -.
DR   BindingDB; Q9H227; -.
DR   ChEMBL; CHEMBL3865; -.
DR   CAZy; GH1; Glycoside Hydrolase Family 1.
DR   iPTMnet; Q9H227; -.
DR   PhosphoSitePlus; Q9H227; -.
DR   DMDM; 77416427; -.
DR   EPD; Q9H227; -.
DR   PaxDb; Q9H227; -.
DR   PeptideAtlas; Q9H227; -.
DR   PRIDE; Q9H227; -.
DR   DNASU; 57733; -.
DR   GeneID; 57733; -.
DR   KEGG; hsa:57733; -.
DR   CTD; 57733; -.
DR   DisGeNET; 57733; -.
DR   GeneCards; GBA3; -.
DR   HGNC; HGNC:19069; GBA3.
DR   MIM; 606619; gene.
DR   neXtProt; NX_Q9H227; -.
DR   PharmGKB; PA134861643; -.
DR   eggNOG; KOG0626; Eukaryota.
DR   eggNOG; COG2723; LUCA.
DR   HOVERGEN; HBG053101; -.
DR   InParanoid; Q9H227; -.
DR   KO; K05350; -.
DR   PhylomeDB; Q9H227; -.
DR   BRENDA; 3.2.1.21; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   SABIO-RK; Q9H227; -.
DR   EvolutionaryTrace; Q9H227; -.
DR   GeneWiki; GBA3; -.
DR   GenomeRNAi; 57733; -.
DR   PRO; PR:Q9H227; -.
DR   Proteomes; UP000005640; Unplaced.
DR   CleanEx; HS_GBA3; -.
DR   GO; GO:1902494; C:catalytic complex; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0004565; F:beta-galactosidase activity; IDA:UniProtKB.
DR   GO; GO:0008422; F:beta-glucosidase activity; IDA:UniProtKB.
DR   GO; GO:0004348; F:glucosylceramidase activity; TAS:Reactome.
DR   GO; GO:0017042; F:glycosylceramidase activity; IDA:UniProtKB.
DR   GO; GO:0102483; F:scopolin beta-glucosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0051692; P:cellular oligosaccharide catabolic process; IDA:CAFA.
DR   GO; GO:0016139; P:glycoside catabolic process; IDA:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0046477; P:glycosylceramide catabolic process; IMP:UniProtKB.
DR   GO; GO:1903017; P:positive regulation of exo-alpha-sialidase activity; IDA:CAFA.
DR   GO; GO:0050821; P:protein stabilization; IDA:CAFA.
DR   InterPro; IPR001360; Glyco_hydro_1.
DR   InterPro; IPR033132; Glyco_hydro_1_N_CS.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR10353; PTHR10353; 1.
DR   Pfam; PF00232; Glyco_hydro_1; 1.
DR   PRINTS; PR00131; GLHYDRLASE1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS00653; GLYCOSYL_HYDROL_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Glycosidase; Hydrolase; Polymorphism; Reference proteome.
FT   CHAIN         1    469       Cytosolic beta-glucosidase.
FT                                /FTId=PRO_0000063908.
FT   REGION      424    425       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    165    165       Proton donor. {ECO:0000255}.
FT   ACT_SITE    373    373       Nucleophile. {ECO:0000255}.
FT   BINDING      17     17       Substrate.
FT   BINDING     120    120       Substrate.
FT   BINDING     164    164       Substrate.
FT   BINDING     309    309       Substrate.
FT   BINDING     417    417       Substrate.
FT   VAR_SEQ      95    401       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015835.
FT   VARIANT     106    106       D -> N (rare polymorphism).
FT                                {ECO:0000269|PubMed:15322500}.
FT                                /FTId=VAR_023587.
FT   VARIANT     172    172       M -> I (in dbSNP:rs36090352).
FT                                /FTId=VAR_049298.
FT   VARIANT     213    213       R -> P (in dbSNP:rs17612341).
FT                                /FTId=VAR_023588.
FT   VARIANT     354    354       C -> R (in dbSNP:rs16873108).
FT                                /FTId=VAR_023589.
FT   MUTAGEN     165    165       E->D: Reduces catalytic activity 2-fold.
FT                                {ECO:0000269|PubMed:17595169,
FT                                ECO:0000269|PubMed:18662675}.
FT   MUTAGEN     165    165       E->Q: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:17595169,
FT                                ECO:0000269|PubMed:18662675}.
FT   MUTAGEN     168    168       V->Y: No change in temperature or pH
FT                                dependence. Decrease in specific
FT                                activity. {ECO:0000269|PubMed:12667141}.
FT   MUTAGEN     225    225       F->S: Decrease in specific activity.
FT                                {ECO:0000269|PubMed:12667141}.
FT   MUTAGEN     308    308       Y->F,A: Decrease in specific activity.
FT                                {ECO:0000269|PubMed:12667141}.
FT   MUTAGEN     373    373       E->D: Reduces catalytic activity 2-fold.
FT                                {ECO:0000269|PubMed:17595169}.
FT   MUTAGEN     373    373       E->Q: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:17595169}.
FT   CONFLICT     29     29       P -> L (in Ref. 6; AAH70188).
FT                                {ECO:0000305}.
FT   CONFLICT    134    134       L -> W (in Ref. 3; AAG39217).
FT                                {ECO:0000305}.
FT   CONFLICT    309    309       Y -> C (in Ref. 5; BAD96683).
FT                                {ECO:0000305}.
FT   CONFLICT    321    321       K -> R (in Ref. 5; BAD96683).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       I -> T (in Ref. 2; CAC08178).
FT                                {ECO:0000305}.
FT   STRAND        8     12       {ECO:0000244|PDB:2E9L}.
FT   HELIX        15     18       {ECO:0000244|PDB:2E9L}.
FT   HELIX        24     26       {ECO:0000244|PDB:2E9L}.
FT   HELIX        31     38       {ECO:0000244|PDB:2E9L}.
FT   STRAND       40     43       {ECO:0000244|PDB:2E9L}.
FT   HELIX        44     46       {ECO:0000244|PDB:2E9L}.
FT   STRAND       49     51       {ECO:0000244|PDB:2E9L}.
FT   TURN         55     57       {ECO:0000244|PDB:2E9L}.
FT   HELIX        59     69       {ECO:0000244|PDB:2E9L}.
FT   STRAND       72     77       {ECO:0000244|PDB:2E9L}.
FT   HELIX        80     83       {ECO:0000244|PDB:2E9L}.
FT   HELIX        94    109       {ECO:0000244|PDB:2E9L}.
FT   STRAND      113    121       {ECO:0000244|PDB:2E9L}.
FT   HELIX       125    129       {ECO:0000244|PDB:2E9L}.
FT   HELIX       132    134       {ECO:0000244|PDB:2E9L}.
FT   HELIX       138    153       {ECO:0000244|PDB:2E9L}.
FT   TURN        154    156       {ECO:0000244|PDB:2E9L}.
FT   STRAND      159    164       {ECO:0000244|PDB:2E9L}.
FT   HELIX       166    174       {ECO:0000244|PDB:2E9L}.
FT   TURN        186    188       {ECO:0000244|PDB:2E9L}.
FT   HELIX       189    211       {ECO:0000244|PDB:2E9L}.
FT   HELIX       213    216       {ECO:0000244|PDB:2E9L}.
FT   STRAND      219    221       {ECO:0000244|PDB:2E9L}.
FT   STRAND      223    233       {ECO:0000244|PDB:2E9L}.
FT   HELIX       237    250       {ECO:0000244|PDB:2E9L}.
FT   HELIX       252    259       {ECO:0000244|PDB:2E9L}.
FT   HELIX       266    278       {ECO:0000244|PDB:2E9L}.
FT   HELIX       291    297       {ECO:0000244|PDB:2E9L}.
FT   STRAND      302    316       {ECO:0000244|PDB:2E9L}.
FT   HELIX       326    330       {ECO:0000244|PDB:2E9L}.
FT   STRAND      332    335       {ECO:0000244|PDB:2E9L}.
FT   HELIX       351    363       {ECO:0000244|PDB:2E9L}.
FT   STRAND      369    374       {ECO:0000244|PDB:2E9L}.
FT   STRAND      378    381       {ECO:0000244|PDB:2E9L}.
FT   HELIX       387    405       {ECO:0000244|PDB:2E9L}.
FT   STRAND      411    417       {ECO:0000244|PDB:2E9L}.
FT   HELIX       425    430       {ECO:0000244|PDB:2E9L}.
FT   STRAND      435    438       {ECO:0000244|PDB:2E9L}.
FT   STRAND      442    444       {ECO:0000244|PDB:2JFE}.
FT   STRAND      447    449       {ECO:0000244|PDB:2E9L}.
FT   HELIX       451    462       {ECO:0000244|PDB:2E9L}.
SQ   SEQUENCE   469 AA;  53696 MW;  9036455485CE2E2F CRC64;
     MAFPAGFGWA AATAAYQVEG GWDADGKGPC VWDTFTHQGG ERVFKNQTGD VACGSYTLWE
     EDLKCIKQLG LTHYRFSLSW SRLLPDGTTG FINQKGIDYY NKIIDDLLKN GVTPIVTLYH
     FDLPQTLEDQ GGWLSEAIIE SFDKYAQFCF STFGDRVKQW ITINEANVLS VMSYDLGMFP
     PGIPHFGTGG YQAAHNLIKA HARSWHSYDS LFRKKQKGMV SLSLFAVWLE PADPNSVSDQ
     EAAKRAITFH LDLFAKPIFI DGDYPEVVKS QIASMSQKQG YPSSRLPEFT EEEKKMIKGT
     ADFFAVQYYT TRLIKYQENK KGELGILQDA EIEFFPDPSW KNVDWIYVVP WGVCKLLKYI
     KDTYNNPVIY ITENGFPQSD PAPLDDTQRW EYFRQTFQEL FKAIQLDKVN LQVYCAWSLL
     DNFEWNQGYS SRFGLFHVDF EDPARPRVPY TSAKEYAKII RNNGLEAHL
//
